Associations Between Urinary Metabolites of Polycyclic Aromatic Hydrocarbons and Liver Enzyme Levels Among Korean Firefighters

Article information

J Prev Med Public Health. 2025;58(6):563-571
Publication date (electronic) : 2025 July 12
doi : https://doi.org/10.3961/jpmph.25.271
1Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
2Department of Occupational and Environmental Health, Yonsei University Graduate School, Seoul, Korea
3Department of Preventive Medicine and Institute of Health Science, Gyeongsang National University College of Medicine, Jinju, Korea
4Department of Occupational and Environmental Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
5Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
6Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
7Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
8Department of Public Health, Yonsei University Graduate School, Seoul, Korea
Corresponding author: Jaelim Cho, Department of Preventive Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea E-mail: chojael@yuhs.ac
Received 2025 April 1; Revised 2025 May 12; Accepted 2025 May 23.

Abstract

Objectives:

Polycyclic aromatic hydrocarbons (PAHs), byproducts of incomplete combustion of organic compounds, have been linked to various adverse health outcomes; however, evidence associating PAHs with liver damage remains inconsistent. This study aimed to investigate the relationship between PAH exposure and liver enzyme levels among firefighters, who have an increased risk of PAH exposure.

Methods:

A total of 961 firefighters were included in the study. Urinary concentrations of 4 PAH metabolites (2-naphthol, 2-hydroxyfluorene, 1-hydroxyphenanthrene, and 1-hydroxypyrene) were measured and categorized into quartiles. Serum levels of liver enzymes, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were evaluated. Age, smoking status, alcohol consumption, body mass index (BMI), job position, and self-reported disease history were adjusted as covariates. Multivariable linear regression analyses were conducted to assess the association between PAH metabolites and serum AST and ALT levels. Logistic regression analyses evaluated associations between PAH metabolites and abnormal AST and ALT levels, defined as 40 IU/L or higher.

Results:

Participants in the highest quartile of urinary 2-naphthol had an increased risk of abnormal ALT levels compared to those in the lowest quartile (odds ratio, 2.00; 95% confidence interval, 1.09 to 3.65). No significant associations were observed for the other PAH metabolites. The association between urinary 2-naphthol and abnormal ALT levels did not differ significantly by smoking status, alcohol consumption, or BMI.

Conclusions:

Elevated urinary 2-naphthol levels were associated with abnormal liver enzyme levels among firefighters, suggesting that monitoring and managing PAH exposure may help protect liver health in this occupational group.

INTRODUCTION

Firefighting is considered one of the most hazardous occupations. Despite firefighters generally maintaining excellent physical fitness, they exhibit a higher risk of cardiovascular diseases and cancers compared to the general population [1-3]. This increased risk can be attributed to unique occupational risk factors inherent to firefighting. Firefighters commonly work irregular shifts and experience unpredictable emergency calls, contributing to inadequate physical activity and unhealthy dietary habits [3,4]. Additionally, they encounter various hazards, including noise, extreme temperatures, and numerous toxic substances at fire scenes [5-7]. Examples of toxic substances present at these scenes include ammonia, carbon monoxide, hydrogen cyanide, nitrogen dioxide, sulfur dioxide, and polycyclic aromatic hydrocarbons (PAHs) [7].

PAHs are a class of organic compounds composed of 2 or more fused aromatic rings produced through the incomplete combustion of organic materials [8]. Exposure to PAHs has been linked to numerous adverse health impacts, including cancer, respiratory disorders, and cardiovascular diseases [9-12]. PAHs are metabolized primarily in the liver, where they can induce oxidative stress and inflammatory responses, potentially leading to hepatocellular injury and consequently affecting systemic health negatively [13].

Only a limited number of studies have explored the relationship between PAHs and liver enzyme levels, which serve as indicators of liver injury [14-17]. A study of 288 petrochemical plant workers reported a positive association between urinary 2-naphthol and serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels [15]. Additionally, a study involving 3194 adolescents from the National Health and Nutrition Examination Survey (NHANES) found positive associations between urinary PAH metabolites and ALT levels [16]. Conversely, a recent study involving 164 firefighters reported a positive association between urinary PAH metabolites and bilirubin levels but did not find a correlation with serum AST and ALT levels [17]. Given these inconsistent results and the limited evidence specifically concerning firefighters, a group highly exposed to PAHs occupationally, this study aimed to evaluate the associations between PAH exposure and abnormal liver enzyme levels among firefighters.

METHODS

Study Participants

The data for this study were obtained from the Firefighter Research on Enhancement of Safety & Health (FRESH) cohort study [18]. The FRESH study was designed as a prospective cohort study to investigate health risk factors among firefighters. A total of 1022 firefighters were recruited from 3 university hospitals (Severance Hospital in Seoul, Wonju Severance Christian Hospital in Wonju, and Gyeongsang National University Hospital in Jinju) between 2016 and 2017. Baseline assessments were initially conducted, followed by 2-year follow-up assessments between 2018 and 2019.

The present study utilized data from the baseline assessment. Among the original 1022 participants, 61 were excluded: 44 female participants and 17 participants with missing or invalid data for exposures and covariates. Thus, the final analysis included 961 participants.

Exposure Assessment

Urine samples were analyzed to determine concentrations of 4 PAH metabolites: 2-naphthol, 2-hydroxyfluorene (2-OHF), 1-hydroxyphenanthrene (1-OHPHE), and 1-hydroxypyrene (1-OHP). All laboratory analyses were conducted by Green Cross Laboratories Co., Ltd. (Yongin, Korea), utilizing gas chromatography–mass spectrometry (GC-MS).

Gas chromatography separation of urinary PAH metabolites was performed using a Clarus 680 (PerkinElmer, Waltham, MA, USA) instrument equipped with a splitless injector and a B-5MS Ultra Inert 122–5532 UI capillary column (30 m×0.25 mm×0.25 μm; Agilent Technologies, Santa Clara, CA, USA). PAH concentrations were normalized to urinary creatinine (μg/gCr) [19] and then divided into quartiles.

Outcome Variable

The outcome variables were serum AST and ALT levels, which are sensitive indicators of liver cell injury [20]. Serum AST and ALT were analyzed both as continuous variables and binary variables, with abnormal defined as serum levels of 40 IU/L or greater, consistent with previous research [15].

Covariates

The covariates included in analyses were age (continuous variable), smoking status (non-smoker, past smoker, and current smoker), alcohol consumption (no drinking; low-risk drinking: ≤40 g/day; moderate to high-risk drinking: >40 g/day) [21], body mass index (BMI), job position (school educators and retirees, fire-control workers, paramedics and rescue workers, and office administrators), and self-reported history of diseases (hypertension, dyslipidemia, and diabetes mellitus).

Statistical Analysis

Descriptive analyses were performed to examine the distribution of general characteristics within the study population. Differences in serum AST and ALT levels according to quartiles of urinary PAH metabolites were examined using the Kruskal-Wallis test (continuous dependent variable) and the chi-square test (binary dependent variable). Multivariable linear regression (for continuous dependent variables) and logistic regression (for binary dependent variables) analyses were conducted to evaluate associations between urinary PAH metabolites and liver enzyme levels after adjusting for the stated covariates.

Post-hoc analyses were conducted to evaluate potential effect modification by BMI (<25 vs. ≥25 kg/m²), smoking status, alcohol consumption status, and job position using stratified analyses. Furthermore, statistical interaction was assessed by comparing regression coefficients across BMI strata using the Altman and Bland test of interaction [22]. A 2-sided p-value of <0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Ethics Statement

All procedures were performed in accordance with the relevant guidelines and regulations of the Declaration of Helsinki. The study’s protocols received approval from the Institutional Review Boards of Severance Hospital, Yonsei University Health System in Seoul, Korea (4-2016-0187), Wonju Severance Christian Hospital in Wonju, Korea (CR316014–002), and Gyeongsang National University Hospital in Jinju, Korea (GNUH 2016-04-015-006). Informed consent was obtained from all participants.

RESULTS

Table 1 summarizes the general characteristics of the study population. Among the 961 participants, the mean age was 42.0 years. Past smokers accounted for 530 participants (55.2%), and 793 participants (82.5%) reported low-risk alcohol consumption. The distribution of job positions was as follows: fire-control workers represented the largest group, with 433 participants (45.1%), while office administrators accounted for 173 participants (18.0%), paramedics and rescue workers comprised 186 participants (19.4%), and school educators and retirees comprised 169 participants (17.6%). The median urinary concentrations of PAH metabolites were 1.76 μg/gCr for 2-naphthol, 0.13 μg/gCr for 2-OHF, 0.12 μg/gCr for 1-OHPHE, and 0.13 μg/gCr for 1-OHP. The median serum AST and ALT levels were 24 IU/L and 23 IU/L, respectively (Table 1).

Demographic and clinical characteristics of the study population

None of the differences in serum AST and ALT levels across quartiles of urinary PAH metabolites reached statistical significance. However, a statistically significant difference was observed in the proportion of abnormal ALT levels among urinary 1-OHPHE quartiles (p-value=0.018); no other significant differences were observed (Table 2).

Serum liver enzyme levels between urinary PAH metabolite quartiles1

Participants in the highest quartile (Q4) of urinary 2-naphthol showed a significantly higher risk of abnormal ALT levels compared to those in the lowest quartile (Q1) (odds ratio [OR], 2.00; 95% confidence interval [CI], 1.09 to 3.65). None of the other metabolites showed statistically significant associations with abnormal liver enzyme levels (Table 3).

Association between urinary PAH metabolites and serum liver enzyme levels1

In the stratified analyses, none of the differences in associations by BMI, smoking status, alcohol consumption, or job position were statistically significant (Figure 1 and Table 4). Notably, among participants with a BMI of 25 kg/m2 or higher, those in the highest quartile (Q4) had an increased risk compared to those in the lowest quartile (Q1) (OR, 2.08; 95% CI, 1.00 to 4.33). In contrast, no significant association was observed among those with a BMI below 25 kg/m2.

Figure. 1.

Association between urinary 2-naphthol and proportion of abnormal alanine aminotransferase (ALT) levels, stratified by body mass index (BMI) status. The models were assessed using multivariable logistic regression, adjusted for age, smoking status, alcohol consumption status, job position, history of diseases. Abnormal ALT levels were defined as 40 IU/L or higher. p-values for comparing adjusted odds ratios across different strata of BMI using the Altman and Bland test of interaction. OR, odds ratio; CI, confidence interval; Q, quartile. *p<0.05.

Association between urinary 2-naphthol and abnormal ALT levels, stratified by smoking status, alcohol consumption, and job position1

DISCUSSION

This study investigated the relationship between PAH exposure and liver enzyme abnormalities among nearly 1000 firefighters, a population highly susceptible to PAH exposure. We identified a positive association between urinary 2-naphthol and abnormal ALT levels among firefighters. This association was consistent across various subgroups, with no significant effect modification observed by BMI, smoking status, alcohol consumption, or job position.

Previous studies have also reported associations between PAH exposure and liver enzyme levels. A cross-sectional study of 288 petrochemical plant workers found a positive relationship between urinary 2-naphthol and serum AST and ALT levels, consistent with our findings [15]. Similarly, a cross-sectional analysis of 3194 adolescents from NHANES revealed that mixed PAH exposure (evaluated through a weighted quantile sum model including 1-naphthol, 2-naphthol, 2-OHF, 3-OHF, 1-OHP, and 1-OHPHE) was associated with elevated ALT levels specifically among female adolescents [16]. Among individual PAH metabolites, only urinary 2-OHF was significantly associated with increased ALT levels. Variations between these findings and our results could stem from differences in the age, gender, ethnicity, or occupational backgrounds of the participants. Another study of 164 firefighters identified a positive association between mixed PAH exposure (assessed via a weighted quantile sum model including 1-naphthol, 2-naphthol, 2-OHF, 3-OHF, 1-OHP, and 2,3-OHPHE) and bilirubin levels, but no association was observed with serum AST and ALT levels [17]. These discrepancies may reflect differences in the age distribution (mean age: 26.4 years) of participants or may be due to the relatively small sample size. Further research on PAH exposure and liver enzyme abnormalities among firefighters is needed to clarify these inconsistencies.

Although job position did not significantly modify the observed effects, the likelihood of abnormal liver enzyme levels associated with PAH exposure tended to be higher among office administrators than among fire-control and rescue workers, who are typically presumed to experience greater exposure to PAHs. In our study, urinary 2-naphthol levels were notably low among fire-control workers (median: 1.62 μg/gCr), comparable to or even lower than those observed in the general Korean population [23]. The absence of elevated urinary PAH metabolites among firefighters likely indicates an underestimation of acute occupational exposures, attributable to the short half-lives of PAHs [24] and the time interval between firefighting activities and sample collection. Nonetheless, these findings provide valuable insights into the chronic or background occupational PAH exposure levels in firefighters [25].

While the biological mechanisms underlying the hepatotoxic effects of PAH exposure remain incompletely understood, several potential mechanisms have been proposed. PAHs are known to induce oxidative stress via reactive oxygen species production, resulting in mitochondrial dysfunction and lipid peroxidation in hepatocytes [13,26]. Additionally, animal studies have demonstrated that PAH exposure can alter liver lipid profiles, potentially leading to hepatocyte membrane damage, inflammation, and non-alcoholic fatty liver disease [27,28]. Notably, naphthalene, the parent compound of 2-naphthol, exhibits unique hepatotoxic properties due to metabolic activation to 1,2-naphthoquinone [29]. This redox-active quinone depletes glutathione, promotes reactive oxygen species overproduction through mitochondrial redox cycling, and directly damages hepatocyte membranes through covalent binding [29,30]. In contrast, other PAH metabolites analyzed in this study typically undergo detoxification via glucuronidation or sulfation without generating persistent oxidative intermediates [31]. The distinct hepatotoxic mechanism of naphthalene, along with relatively lower variability in levels of other PAH metabolites in our study population, may explain why only 2-naphthol showed significant associations with elevated liver enzymes in this study. Moreover, the observed association specifically with ALT, a more liver-specific marker than AST, further supports the biological plausibility of naphthalene-induced hepatocellular injury in this context [32].

This study has several limitations. First, we used cross-sectional data, with urinary PAH metabolite data available only at baseline. Thus, a temporal relationship between PAH exposure and liver enzyme abnormalities cannot be definitively established. Second, despite adjusting for age, BMI, smoking status, and other relevant factors, residual confounding may still exist. Although stratified analyses by BMI, smoking status, alcohol consumption, and job position showed no significant effect modification, unmeasured confounders such as physical activity or exposure to other pollutants (e.g., per- and polyfluoroalkyl substances, volatile organic compounds) could influence our findings. Third, correction for multiple testing was not applied, aligning with the exploratory nature of the study. Lastly, this study included only man firefighters, limiting our understanding of potential effects in women, who might exhibit different toxicological responses to PAH exposure compared with men [33]. Furthermore, our findings may not be generalizable to the broader population or other occupational groups due to the unique exposure patterns among firefighters and potential healthy-worker effects inherent in occupational cohorts.

In conclusion, our study found associations between urinary 2-naphthol levels and abnormal ALT levels among firefighters. Although these results should be interpreted cautiously considering study limitations, they indicate that monitoring and managing PAH exposure may play an important role in protecting the liver health of firefighters.

Notes

Conflict of Interest

The authors have no conflicts of interest associated with the material presented in this paper.

Funding

This work was supported by the Fire Fighting Safety & 119 Rescue Technology Research and Development Program funded by the National Fire Agency ("MPSS-Firesafety-2015-80") and Smart HealthCare Program (www.kipot.or.kr) funded by the Korean National Police Agency (KNPA, Korea) [Project Name: Precision & Personalized Medicine for Predicting Cardiovascular Disease Risk in Police Officers (4Ps study) / Project Number: 220222M02].

Acknowledgements

None.

Author Contributions

Conceptualization: Lee J. Data curation: Bae MJ, Kim MJ, Oh SS, Park KS, Lee CJ, Park S, Lee SK, Koh SB, Kim C. Formal analysis: Lee J. Funding acquisition: Park KS, Koh SB, Kim C. Methodology: Lee J, Park KS, Park S, Koh SB, Kim HC, Kim C, Cho J. Project administration: Park KS, Koh SB, Kim C. Visualization: Lee J. Writing – original draft: Lee J. Writing – review & editing: Bae MJ, Kim MJ, Oh SS, Park KS, Lee CJ, Park S, Lee SK, Koh SB, Kim HC, Kim C, Cho J.

References

1. LeMasters GK, Genaidy AM, Succop P, Deddens J, Sobeih T, Barriera-Viruet H, et al. Cancer risk among firefighters: a review and meta-analysis of 32 studies. J Occup Environ Med 2006;48(11):1189–1202. https://doi.org/10.1097/01.jom.0000246229.68697.90.
2. Daniels RD, Bertke S, Dahm MM, Yiin JH, Kubale TL, Hales TR, et al. Exposure-response relationships for select cancer and non-cancer health outcomes in a cohort of U.S. firefighters from San Francisco, Chicago and Philadelphia (1950-2009). Occup Environ Med 2015;72(10):699–706. https://doi.org/10.1136/oemed-2014-102671.
3. Soteriades ES, Smith DL, Tsismenakis AJ, Baur DM, Kales SN. Cardiovascular disease in US firefighters: a systematic review. Cardiol Rev 2011;19(4):202–215. https://doi.org/10.1097/CRD.0b013e318215c105.
4. Lowden A, Moreno C, Holmbäck U, Lennernäs M, Tucker P. Eating and shift work - effects on habits, metabolism and performance. Scand J Work Environ Health 2010;36(2):150–162. https://doi.org/10.5271/sjweh.2898.
5. Barros B, Oliveira M, Morais S. Firefighters’ occupational exposure: contribution from biomarkers of effect to assess health risks. Environ Int 2021;156:106704. https://doi.org/10.1016/j.envint.2021.106704.
6. Smith DL, Petruzzello SJ, Chludzinski MA, Reed JJ, Woods JA. Selected hormonal and immunological responses to strenuous live-fire firefighting drills. Ergonomics 2005;48(1):55–65. https://doi.org/10.1080/00140130412331303911.
7. Fabian TZ, Borgerson JL, Gandhi PD, Baxter CS, Ross CS, Lockey JE, et al. Characterization of firefighter smoke exposure. Fire Technol 2014;50:993–1019. https://doi.org/10.1007/s10694-011-0212-2.
8. Kim KH, Jahan SA, Kabir E, Brown RJ. A review of airborne polycyclic aromatic hydrocarbons (PAHs) and their human health effects. Environ Int 2013;60:71–80. https://doi.org/10.1016/j.envint.2013.07.019.
9. Mastrangelo G, Fadda E, Marzia V. Polycyclic aromatic hydrocarbons and cancer in man. Environ Health Perspect 1996;104(11):1166–1170. https://doi.org/10.1289/ehp.961041166.
10. Armstrong B, Hutchinson E, Unwin J, Fletcher T. Lung cancer risk after exposure to polycyclic aromatic hydrocarbons: a review and meta-analysis. Environ Health Perspect 2004;112(9):970–978. https://doi.org/10.1289/ehp.6895.
11. Låg M, Øvrevik J, Refsnes M, Holme JA. Potential role of polycyclic aromatic hydrocarbons in air pollution-induced non-malignant respiratory diseases. Respir Res 2020;21(1):299. https://doi.org/10.1186/s12931-020-01563-1.
12. Poursafa P, Moosazadeh M, Abedini E, Hajizadeh Y, Mansourian M, Pourzamani H, et al. A systematic review on the effects of polycyclic aromatic hydrocarbons on cardiometabolic impairment. Int J Prev Med 2017;8:19. https://doi.org/10.4103/ijpvm.IJPVM_144_17.
13. Ma H, Wang H, Zhang H, Guo H, Zhang W, Hu F, et al. Effects of phenanthrene on oxidative stress and inflammation in lung and liver of female rats. Environ Toxicol 2020;35(1):37–46. https://doi.org/10.1002/tox.22840.
14. Efriza E, Alshahrani SH, Zekiy AO, Al-Awsi GR, Sharma SK, Ramírez-Coronel AA, et al. Exposure to polycyclic aromatic hydrocarbons and liver function: a systematic review of observational studies. Air Qual Atmos Health 2023;16(5):1079–1088. https://doi.org/10.1007/s11869-023-01324-1.
15. Min YS, Lim HS, Kim H. Biomarkers for polycyclic aromatic hydrocarbons and serum liver enzymes. Am J Ind Med 2015;58(7):764–772. https://doi.org/10.1002/ajim.22463.
16. Xu C, Liu Q, Liang J, Weng Z, Xu J, Jiang Z, et al. Urinary biomarkers of polycyclic aromatic hydrocarbons and their associations with liver function in adolescents. Environ Pollut 2021;278:116842. https://doi.org/10.1016/j.envpol.2021.116842.
17. Pálešová N, Maitre L, Stratakis N, Řiháčková K, Pindur A, Kohoutek J, et al. Firefighters and the liver: exposure to PFAS and PAHs in relation to liver function and serum lipids (CELSPAC-FIREexpo study). Int J Hyg Environ Health 2023;252:114215. https://doi.org/10.1016/j.ijheh.2023.114215.
18. Kim YT, Kim WJ, Choi JE, Bae MJ, Jang H, Lee CJ, et al. Cohort profile: Firefighter Research on the Enhancement of Safety and Health (FRESH), a prospective cohort study on Korean firefighters. Yonsei Med J 2020;61(1):103–109. https://doi.org/10.3349/ymj.2020.61.1.103.
19. Viau C, Lafontaine M, Payan JP. Creatinine normalization in biological monitoring revisited: the case of 1-hydroxypyrene. Int Arch Occup Environ Health 2004;77(3):177–185. https://doi.org/10.1007/s00420-003-0495-9.
20. Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly elevated liver transaminase levels: causes and evaluation. Am Fam Physician 2017;96(11):709–715.
21. Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS, Falk DE, et al. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin Exp Res 2017;41(1):179–186. https://doi.org/10.1111/acer.13272.
22. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. https://doi.org/10.1136/bmj.326.7382.219.
23. Jung SK, Choi W, Kim SY, Hong S, Jeon HL, Joo Y, et al. Profile of environmental chemicals in the Korean population-results of the Korean National Environmental Health Survey (KoNEHS) cycle 3, 2015-2017. Int J Environ Res Public Health 2022;19(2):626. https://doi.org/10.3390/ijerph19020626.
24. Ciarrocca M, Rosati MV, Tomei F, Capozzella A, Andreozzi G, Tomei G, et al. Is urinary 1-hydroxypyrene a valid biomarker for exposure to air pollution in outdoor workers? A meta-analysis. J Expo Sci Environ Epidemiol 2014;24(1):17–26. https://doi.org/10.1038/jes.2012.111.
25. Dobraca D, Lum R, Sjödin A, Calafat AM, Laurent CA, Kushi LH, et al. Urinary biomarkers of polycyclic aromatic hydrocarbons in pre- and peri-pubertal girls in Northern California: predictors of exposure and temporal variability. Environ Res 2018;165:46–54. https://doi.org/10.1016/j.envres.2017.11.011.
26. van Meteren N, Lagadic-Gossmann D, Podechard N, Gobart D, Gallais I, Chevanne M, et al. Extracellular vesicles released by polycyclic aromatic hydrocarbons-treated hepatocytes trigger oxidative stress in recipient hepatocytes by delivering iron. Free Radic Biol Med 2020;160:246–262. https://doi.org/10.1016/j.freeradbiomed.2020.08.001.
27. Li F, Xiang B, Jin Y, Li C, Ren S, Wu Y, et al. Hepatotoxic effects of inhalation exposure to polycyclic aromatic hydrocarbons on lipid metabolism of C57BL/6 mice. Environ Int 2020;134:105000. https://doi.org/10.1016/j.envint.2019.105000.
28. Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev 2018;2018:9547613. https://doi.org/10.1155/2018/9547613.
29. Wilson AS, Davis CD, Williams DP, Buckpitt AR, Pirmohamed M, Park BK. Characterisation of the toxic metabolite(s) of naphthalene. Toxicology 1996;114(3):233–242. https://doi.org/10.1016/s0300-483x(96)03515-9.
30. Soares AG, Muscara MN, Costa SK. Molecular mechanism and health effects of 1,2-Naphtoquinone. EXCLI J 2020;19:707–717. https://doi.org/10.17179/excli2020-1210.
31. Shangari N, Chan TS, O’Brien PJ. Sulfation and glucuronidation of phenols: implications in coenyzme Q metabolism. Methods Enzymol 2005;400:342–359. https://doi.org/10.1016/S0076-6879(05)00020-0.
32. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342(17):1266–1271. https://doi.org/10.1056/NEJM200004273421707.
33. Guo H, Huang K, Zhang X, Zhang W, Guan L, Kuang D, et al. Women are more susceptible than men to oxidative stress and chromosome damage caused by polycyclic aromatic hydrocarbons exposure. Environ Mol Mutagen 2014;55(6):472–481. https://doi.org/10.1002/em.21866.

Article information Continued

Figure. 1.

Association between urinary 2-naphthol and proportion of abnormal alanine aminotransferase (ALT) levels, stratified by body mass index (BMI) status. The models were assessed using multivariable logistic regression, adjusted for age, smoking status, alcohol consumption status, job position, history of diseases. Abnormal ALT levels were defined as 40 IU/L or higher. p-values for comparing adjusted odds ratios across different strata of BMI using the Altman and Bland test of interaction. OR, odds ratio; CI, confidence interval; Q, quartile. *p<0.05.

Table 1.

Demographic and clinical characteristics of the study population

Characteristics Total (n = 961)
Age (y) 42.0±10.7
Body mass index (kg/m2) 24.9±2.6
Smoking status
 Non-smoker 329 (34.2)
 Past smoker 530 (55.2)
 Current smoker 102 (10.6)
Alcohol consumption
 No drinking 70 (7.3)
 Low-risk drinking 793 (82.5)
 Moderate to high-risk drinking 98 (10.2)
Job position
 School educators and retirees 169 (17.6)
 Fire-control workers 433 (45.1)
 Paramedics and rescue workers 186 (19.4)
 Office administrators 173 (18.0)
History of disease
 Hypertension 104 (10.8)
 Dyslipidemia 72 (7.5)
 Diabetes mellitus 32 (3.3)
Urinary PAH metabolites (μg/gCr)
 2-naphthol 1.76 [0.73-4.95]
 2-OHF 0.13 [0.08-0.31]
 1-OHPHE 0.12 [0.08-0.18]
 1-OHP 0.13 [0.09-0.21]
AST level 24.0 [21.0-29.0]
 Abnormal AST level1 81 (8.4)
ALT level 23.0 [18.0-32.0]
 Abnormal ALT level1 140 (14.6)

Values are presented as mean±standard deviation, number (%), or median [interquartile range].

PAH, polycyclic aromatic hydrocarbon; Cr, creatinine; 2-OHF, 2-hydroxyfluorene; 1-OHPHE, 1-hydroxyphenanthrene; 1-OHP, 1-hydroxypyrene; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

1

Abnormal AST and ALT levels were defined as 40 IU/L or higher.

Table 2.

Serum liver enzyme levels between urinary PAH metabolite quartiles1

Variables AST p-value ALT p-value AST
p-value ALT
p-value
Normal Abnormal2 Normal Abnormal2
Urinary 2-naphthol 0.389 0.150 0.898 0.089
 Q1 (0.00-0.73) 24.0 [21.0-28.0] 23.0 [19.0-29.0] 221 (92.1) 19 (7.9) 221 (92.1) 19 (7.9)
 Q2 (0.73-1.76) 25.0 [22.0-29.0] 24.0 [18.0-31.0] 220 (91.7) 20 (8.3) 220 (91.7) 20 (8.3)
 Q3 (1.76-4.95) 24.0 [21.0-30.0] 22.0 [17.0-31.0] 222 (92.1) 19 (7.9) 222 (92.1) 19 (7.9)
 Q4 (5.03-42.20) 24.0 [21.8-30.0] 24.0 [18.0-33.2] 217 (90.4) 23 (9.6) 217 (90.4) 23 (9.6)
Urinary 2-OHF 0.597 0.371 0.712 0.207
 Q1 (0.00-0.08) 24.0 [21.0-29.0] 23.5 [18.0-32.0] 219 (91.2) 21 (8.8) 219 (91.2) 21 (8.8)
 Q2 (0.08-0.13) 24.0 [21.0-30.0] 22.0 [18.0-31.0] 218 (90.8) 22 (9.2) 218 (90.8) 22 (9.2)
 Q3 (0.13-0.31) 25.0 [22.0-28.0] 23.0 [18.0-30.0] 225 (93.4) 16 (6.6) 225 (93.4) 16 (6.6)
 Q4 (0.31-1.90) 24.5 [22.0-30.0] 24.0 [18.0-34.0] 218 (90.8) 22 (9.2) 218 (90.8) 22 (9.2)
Urinary 1-OHPHE 0.625 0.113 0.172 0.018
 Q1 (0.00-0.08) 24.0 [21.0-30.0] 23.0 [18.0-31.0] 216 (90.0) 24 (10.0) 216 (90.0) 24 (10.0)
 Q2 (0.08-0.12) 24.0 [21.0-29.0] 25.0 [19.0-33.0] 217 (90.4) 23 (9.6) 217 (90.4) 23 (9.6)
 Q3 (0.12-0.18) 25.0 [21.0-30.0] 23.0 [18.0-33.0] 219 (90.9) 22 (9.1) 219 (90.9) 22 (9.1)
 Q4 (0.18-3.80) 25.0 [22.0-29.0] 23.0 [18.0-30.0] 228 (95.0) 12 (5.0) 228 (95.0) 12 (5.0)
Urinary 1-OHP 0.779 0.909 0.455 0.452
 Q1 (0.00-0.09) 24.5 [21.0-30.0] 22.0 [18.0-31.0] 215 (89.6) 25 (10.4) 215 (89.6) 25 (10.4)
 Q2 (0.09-0.13) 24.0 [21.0-30.0] 24.0 [18.0-33.0] 224 (93.3) 16 (6.7) 224 (93.3) 16 (6.7)
 Q3 (0.13-0.21) 24.0 [22.0-29.0] 23.0 [18.0-31.0] 219 (90.9) 22 (9.1) 219 (90.9) 22 (9.1)
 Q4 (0.21-8.93) 25.0 [22.0-29.0] 24.0 [18.0-31.0] 222 (92.5) 18 (7.5) 222 (92.5) 18 (7.5)

Values are presented as median [interquartile range] or number (%).

PAH, polycyclic aromatic hydrocarbon; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 2-OHF, 2-hydroxyfluorene; 1-OHPHE, 1-hydroxyphenanthrene; 1-OHP, 1-hydroxypyrene.

1

The comparison of AST and ALT levels was performed using the Kruskal-Wallis test, and the comparison of the proportion of abnormal AST and ALT levels was performed using the chi-square test.

2

Abnormal AST and ALT levels were defined as 40 IU/L or higher.

Table 3.

Association between urinary PAH metabolites and serum liver enzyme levels1

Variables β (95% CI)
OR (95% CI)
AST ALT Abnormal AST2 Abnormal ALT2
Urinary 2-naphthol
 Q1 Reference Reference 1.00 (reference) 1.00 (reference)
 Q2 -2.826 (-9.577, 3.925) 0.814 (-2.983, 4.611) 0.96 (0.49, 1.90) 1.56 (0.87, 2.79)
 Q3 -2.134 (-8.962, 4.694) 0.877 (-2.964, 4.717) 0.93 (0.46, 1.86) 1.37 (0.75, 2.50)
 Q4 -0.106 (-7.432, 7.219) 1.686 (-2.434, 5.806) 1.08 (0.53, 2.22) 2.00 (1.09, 3.65)*
Urinary 2-OHF
 Q1 Reference Reference 1.00 (reference) 1.00 (reference)
 Q2 -4.073 (-10.924, 2.779) -2.558 (-6.408, 1.292) 1.10 (0.56, 2.14) 1.32 (0.76, 2.29)
 Q3 -4.689 (-11.509, 2.131) -2.760 (-6.592, 1.072) 0.73 (0.36, 1.49) 0.82 (0.45, 1.48)
 Q4 -1.138 (-8.494, 6.218) 0.052 (-4.082, 4.186) 1.01 (0.49, 2.08) 1.42 (0.79, 2.56)
Urinary 1-OHPHE
 Q1 Reference Reference 1.00 (reference) 1.00 (reference)
 Q2 -3.741 (-10.527, 3.044) -0.817 (-4.635, 3.001) 0.83 (0.44, 1.56) 1.32 (0.78, 2.25)
 Q3 -3.785 (-10.661, 3.091) -0.945 (-4.814, 2.924) 0.93 (0.49, 1.79) 1.59 (0.92, 2.75)
 Q4 -3.546 (-10.432, 3.339) -1.229 (-5.103, 2.646) 0.52 (0.24, 1.10) 0.74 (0.40, 1.37)
Urinary 1-OHP
 Q1 Reference Reference 1.00 (reference) 1.00 (reference)
 Q2 -6.389 (-13.169, 0.390) -1.321 (-5.138, 2.496) 0.66 (0.34, 1.31) 0.90 (0.53, 1.53)
 Q3 -4.435 (-11.274, 2.404) -0.147 (-3.998, 3.704) 0.93 (0.49, 1.78) 0.82 (0.48, 1.42)
 Q4 -3.041 (-9.861, 3.779) 0.592 (-3.248, 4.432) 0.84 (0.43, 1.63) 0.87 (0.50, 1.50)

PAH, polycyclic aromatic hydrocarbon; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; OR, odds ratio; Q, quartile; 2-OHF, 2-hydroxyfluorene; 1-OHPHE, 1-hydroxyphenanthrene; 1-OHP, 1-hydroxypyrene.

1

The models with AST and ALT levels were assessed using multivariable linear regression, and the models with proportion of abnormal AST and ALT levels were assessed using multivariable logistic regression; Models were adjusted for age, smoking status, alcohol consumption, body mass index, job position, and history of diseases.

2

Abnormal AST and ALT levels were defined as 40 IU/L or higher.

*

p<0.05.

Table 4.

Association between urinary 2-naphthol and abnormal ALT levels, stratified by smoking status, alcohol consumption, and job position1

Variables Abnormal ALT2
Q1 Q2 Q3 Q4
Smoking status
 Non-smoker (n = 329) 1.00 (reference) 2.16 (0.70, 6.67) 2.90 (0.96, 8.76) 1.80 (0.55, 5.87)
 Past smoker (n = 530) 1.00 (reference) 0.60 (0.27, 1.35) 1.20 (0.56, 2.53) 1.50 (0.73, 3.10)
 Current smoker (n = 102) 1.00 (reference) 4.01 (0.72, 22.34) 2.56 (0.44, 15.00) 0.87 (0.11, 6.51)
Alcohol consumption
 No drinking (n = 70) 1.00 (reference) 0.43 (0.01, 13.71) 0.62 (0.02, 22.19) 0.32 (0.01, 17.48)
 Low-risk drinking (n = 793) 1.00 (reference) 1.78 (0.94, 3.36) 1.47 (0.75, 2.87) 2.25 (1.16, 4.36)
 Moderate to high-risk drinking (n = 98) 1.00 (reference) 0.08 (0.01, 1.01) 0.71 (0.14, 3.57) 0.20 (0.03, 1.49)
Job position
 School educators and retirees (n = 169) 1.00 (reference) 2.24 (0.49, 10.24) 0.77 (0.11, 5.41) 2.40 (0.49, 11.74)
 Fire-control workers (n = 433) 1.00 (reference) 0.79 (0.31, 2.04) 1.26 (0.52, 3.08) 1.49 (0.59, 3.76)
 Paramedics and rescue workers (n = 186) 1.00 (reference) 1.53 (0.36, 6.58) 1.64 (0.35, 7.63) 1.32 (0.22, 7.75)
 Office administrators (n = 173) 1.00 (reference) 0.71 (0.20, 2.57) 1.37 (0.42, 4.50) 2.39 (0.73, 7.84)

Values are presented odds ratio (95% confidence interval).

ALT, alanine aminotransferase; Q, quartile.

1

The models were assessed using multivariable logistic regression, adjusted for age, smoking status, alcohol consumption, body mass index, job position, history of diseases.

2

Abnormal ALT levels were defined as 40 IU/L or higher.